This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Aug 10;40(23):2657-2658.

doi: 10.1200/JCO.22.00809. Epub 2022 May 24.

Reply to S. Zhang

Michael Lattanzi¹, Samuel A Funt¹, Jonathan E Rosenberg¹

Affiliations

PMID: 35609227
DOI: 10.1200/JCO.22.00809

Comment

Reply to S. Zhang

Michael Lattanzi et al. J Clin Oncol. 2022.

. 2022 Aug 10;40(23):2657-2658.

doi: 10.1200/JCO.22.00809. Epub 2022 May 24.

Authors

Michael Lattanzi¹, Samuel A Funt¹, Jonathan E Rosenberg¹

Affiliation

¹ Michael Lattanzi, MD, Samuel A. Funt, MD, and Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY.

PMID: 35609227
DOI: 10.1200/JCO.22.00809

No abstract available

PubMed Disclaimer

Comment on

Neoadjuvant Programmed Cell Death Protein 1 and Chemotherapy in Combination in Muscle-Invasive Urothelial Cancer: Promising, But Not Deserving to Try Further.
Zhang S. Zhang S. J Clin Oncol. 2022 Aug 10;40(23):2656. doi: 10.1200/JCO.22.00420. Epub 2022 May 24. J Clin Oncol. 2022. PMID: 35609220 No abstract available.

Publication types

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.